SA PRO
Free Account
Abiomed, Inc.ABMDNASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

IoMT Wearable Devices Patent Landscape Report and Forecasts, 2017-2023 & 2024-2032 Featuring Veniam, Advanced Neuromodulation Systems, Bionet Sonar, and Abiomed
globenewswire.com

IoMT Wearable Devices Patent Landscape Report and Forecasts, 2017-2023 & 2024-2032 Featuring Veniam, Advanced Neuromodulation Systems, Bionet Sonar, and Abiomed

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "IoMT Wearable Devices Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The IoMT wearable devices market was valued at USD 34.93 billion in 2023. It is expected to grow at a CAGR of 23.0% during the forecast period of 2024-2032 and attain a market value of USD 225.1 billion in 2032. The patent landscape is driven by advancements in sensor technology, AI integration, and connectivity solutions, enhancing diagnostic accuracy and personalised treatment. The global IoMT wearable devices patent landscape report offers an in-depth analysis of the dynamic patent environment. It explores innovations in sensor technologies, AI integration, and advanced connectivity solutions that are shaping the future of IoMT wearables. The report provides detailed segmentation by product type, modality, and application, highlighting key patents and emerging trends.

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
businesswire.com

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

DANVERS, Mass.--( BUSINESS WIRE )--Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI).

Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022
businesswire.com

Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022

NEW BRUNSWICK, N.J.--( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ), the world's largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. (“Offeror”), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the “Offer”) to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ: ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD
prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Elevate Credit, Inc. (NYSE: ELVT)'s  sale to an affiliate of Park Cities Asset Management LLC for $1.87 per share. If you are an Elevate Credit shareholder, click here to learn more about your rights and options.

First Patients in the World Treated with Impella RP Flex with SmartAssist
businesswire.com

First Patients in the World Treated with Impella RP Flex with SmartAssist

DANVERS, Mass.--( BUSINESS WIRE )--Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed's newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their native heart. The patients were treated at Hackensack University Medical Center/Hackensack Meridian Health in Hackensack, N.J., and Kingwood Medical Center in Kingwood, Texas.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ABIOMED, Inc. Buyout
newsfilecorp.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ABIOMED, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - November 4, 2022) - Rigrodsky Law, P.A. is investigating ABIOMED, Inc. ("ABIOMED") (NASDAQ: ABMD) regarding possible breaches of fiduciary duties and other violations of law related to ABIOMED's agreement to be acquired by Johnson & Johnson. Under the terms of the agreement, ABIOMED's shareholders will receive $380.00 in cash plus one contingent value right per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-abiomed-inc.To contact Seth D.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATCO, ABMD, BNFT
prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATCO, ABMD, BNFT

NEW YORK , Nov. 2, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atlas Corp. (NYSE: ATCO)'s  sale to Poseidon Acquisition Corp. for $15.50 per share in cash. If you are an Atlas shareholder, click here to learn more about your rights and options.

SHAREHOLDER ALERT: Weiss Law Investigates Abiomed, Inc.
prnewswire.com

SHAREHOLDER ALERT: Weiss Law Investigates Abiomed, Inc.

NEW YORK , Nov. 1, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Abiomed, Inc. ("Abiomed" or the "Company") (NASDAQ: ABMD), in connection with its proposed tender offer by Johnson & Johnson (NYSE: JNJ). Under the tender offer, the Company's shareholders will receive $380.00 in cash, reflecting an enterprise value of approximately $16.6 billion, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $35.00 for each share of Abiomed common stock owned.

Abiomed Shares Pop 50% on Johnson & Johnson Buyout
gurufocus.com

Abiomed Shares Pop 50% on Johnson & Johnson Buyout

Marking its biggest deal in nearly six years, Johnson & Johnson ( JNJ , Financial) announced on Tuesday it is buying Abiomed Inc. ( ABMD , Financial) for $16.6 billion in a bid to boost its cardiovascular business even as its spins off its consumer health division.

Abiomed, Inc. (ABMD) Q2 2023 Earnings Call Transcript
seekingalpha.com

Abiomed, Inc. (ABMD) Q2 2023 Earnings Call Transcript

Abiomed, Inc. (NASDAQ:ABMD ) Q2 2023 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Jessica Moore - Vice President of Investor Relations, Johnson & Johnson. Joaquin Duato - Chief Executive Officer, Johnson & Johnson Michael Joaquin - Chairman, President and Chief Executive Officer Ashley McEvoy - Executive Vice President and Worldwide Chairman, Medtech Johnson & Johnson Joe Wolk - Chief Financial Officer, Johnson & Johnson Conference Call Participants Joanne Wuensch - Citibank Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Jayson Bedford - Raymond James Terence Flynn - Morgan Stanley Operator Its now pleasure to turn the conference over Vice President of Investor Relations, Jessica Moore.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance